$GH · Guardant Health, Inc.
Guardant Health reported Q3 FY2026 results: revenue of $361.0M, up 36% YoY from $265.2M, driven by Oncology (+25% to $231.3M) and Screening (+180% to $67.6M). GAAP net loss widened to $124.4M ($0.93/share) from $92.7M, while non-GAAP net loss narrowed to $38.8M ($0.29/share). The company raised FY2026 revenue guidance to $1.36–1.37B (38–40% growth) from $1.34–1.36B, and raised Screening revenue guidance to $233–238M on 285,000–290,000 Shield tests. Cash, cash equivalents, and restricted cash totaled $1.1B at quarter-end.
- Q3 revenue $361.0M, +36% YoY from $265.2M.
- Screening revenue +180% to $67.6M on 83,000 Shield tests (+246%).
- Oncology volume +58% to 117,000 tests; revenue +25% to $231.3M.
- GAAP net loss widened to $124.4M ($0.93/share) from $92.7M.
- FY2026 revenue guidance raised to $1.36–1.37B, 38–40% growth.
Extended-hours last trade $136.99, down 10.71% vs the $153.43 regular close, despite the guidance raise — the market is weighing the widened GAAP loss and higher guided free cash flow burn against strong top-line growth.
A 36% revenue beat and raised guidance collided with a widening GAAP loss and higher cash burn, driving a double-digit after-hours selloff.
Shield's 180% screening growth and FDA companion-diagnostic approvals (Guardant360 CDx for camizestrant and imlunestrant) position Guardant against Exact Sciences in the blood-based cancer screening race.
Free cash flow burn guidance was raised to $205–220M for FY2026, and non-GAAP operating expense guidance increased to $1.105–1.125B, reflecting heavy commercial infrastructure spend to support Screening and Oncology growth.